- Home
- SCPH vs OCGN Comparison
SCPH vs OCGN Comparison
Compare SCPH & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- OCGN
- Stock Information
- Founded
- SCPH 2013
- OCGN 2013
- Country
- SCPH United States
- OCGN United States
- Employees
- SCPH N/A
- OCGN N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCPH Health Care
- OCGN Health Care
- Exchange
- SCPH Nasdaq
- OCGN Nasdaq
- Market Cap
- SCPH 173.6M
- OCGN 189.6M
- IPO Year
- SCPH 2017
- OCGN N/A
- Fundamental
- Price
- SCPH $2.57
- OCGN $0.68
- Analyst Decision
- SCPH Strong Buy
- OCGN Strong Buy
- Analyst Count
- SCPH 3
- OCGN 3
- Target Price
- SCPH $14.00
- OCGN $6.33
- AVG Volume (30 Days)
- SCPH 519.0K
- OCGN 4.3M
- Earning Date
- SCPH 05-13-2025
- OCGN 05-13-2025
- Dividend Yield
- SCPH N/A
- OCGN N/A
- EPS Growth
- SCPH N/A
- OCGN N/A
- EPS
- SCPH N/A
- OCGN N/A
- Revenue
- SCPH $36,332,000.00
- OCGN $4,054,999.00
- Revenue This Year
- SCPH $114.00
- OCGN N/A
- Revenue Next Year
- SCPH $77.45
- OCGN N/A
- P/E Ratio
- SCPH N/A
- OCGN N/A
- Revenue Growth
- SCPH 167.28
- OCGN N/A
- 52 Week Low
- SCPH $1.94
- OCGN $0.52
- 52 Week High
- SCPH $5.65
- OCGN $2.06
- Technical
- Relative Strength Index (RSI)
- SCPH 47.35
- OCGN 51.84
- Support Level
- SCPH $1.94
- OCGN $0.64
- Resistance Level
- SCPH $2.71
- OCGN $0.74
- Average True Range (ATR)
- SCPH 0.27
- OCGN 0.07
- MACD
- SCPH 0.04
- OCGN 0.00
- Stochastic Oscillator
- SCPH 76.36
- OCGN 54.50
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").